ScreenCell is a French company currently based in Paris area. It was founded with the objective of designing and producing a simple and disposable technology allowing the fast and effective isolation of Circulating Tumor Cells (CTC) from cancer patient’s blood.
After being isolated, CTC can be analyzed to provide cellular and molecular characterization that are important for cancer monitoring.
To date, tumor biopsies offer comprehensive molecular analysis of tumor cells. This is an essential aspect in patient management to guide precision and personalized therapy. However, tissue biopsies are often challenging and practically after surgery there is no tumor material available for patient follow-up. With the evolution of precision medicine technologies, CTC can offer same information as initial tumor biopsies, and are therefore considered as liquid biopsies.
ScreenCell technology isolates high quality CTCs enabling noninvasive, easy and fast access to precision medicine.
R&D Team
Commercial affairs and Communication
Production and Quality/Regulatory affairs
